Genic (Korea) Technical Analysis
123330 Stock | KRW 21,250 1,000.00 4.49% |
As of the 23rd of December, Genic retains the Market Risk Adjusted Performance of (0.91), downside deviation of 4.28, and Risk Adjusted Performance of 0.0821. Genic technical analysis makes it possible for you to employ historical prices and volume momentum with the intention to determine a pattern that calculates the direction of the firm's future prices.
Genic Momentum Analysis
Momentum indicators are widely used technical indicators which help to measure the pace at which the price of specific equity, such as Genic, fluctuates. Many momentum indicators also complement each other and can be helpful when the market is rising or falling as compared to GenicGenic |
Genic technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.
Genic Technical Analysis
Incorrect Input. Please change your parameters or increase the time horizon required for running this function. The output start index for this execution was zero with a total number of output elements of zero. The Average True Range was developed by J. Welles Wilder in 1970s. It is one of components of the Welles Wilder Directional Movement indicators. The ATR is a measure of Genic volatility. High ATR values indicate high volatility, and low values indicate low volatility.
Genic Trend Analysis
Use this graph to draw trend lines for Genic Co. You can use it to identify possible trend reversals for Genic as well as other signals and approximate when it will take place. Remember, you need at least two touches of the trend line with actual Genic price movement. To start drawing, click on the pencil icon on top-right. To remove the trend, use eraser icon.Genic Best Fit Change Line
The following chart estimates an ordinary least squares regression model for Genic Co applied against its price change over selected period. The best fit line has a slop of 12.03 , which may suggest that Genic Co market price will keep on failing further. It has 122 observation points and a regression sum of squares at 5471068.6, which is the sum of squared deviations for the predicted Genic price change compared to its average price change.About Genic Technical Analysis
The technical analysis module can be used to analyzes prices, returns, volume, basic money flow, and other market information and help investors to determine the real value of Genic Co on a daily or weekly bases. We use both bottom-up as well as top-down valuation methodologies to arrive at the intrinsic value of Genic Co based on its technical analysis. In general, a bottom-up approach, as applied to this company, focuses on Genic price pattern first instead of the macroeconomic environment surrounding Genic. By analyzing Genic's financials, daily price indicators, and related drivers such as dividends, momentum ratios, and various types of growth rates, we attempt to find the most accurate representation of Genic's intrinsic value. As compared to a bottom-up approach, our top-down model examines the macroeconomic factors that affect the industry/economy before zooming in to Genic specific price patterns or momentum indicators. Please read more on our technical analysis page.
Genic December 23, 2024 Technical Indicators
Most technical analysis of Genic help investors determine whether a current trend will continue and, if not, when it will shift. We provide a combination of tools to recognize potential entry and exit points for Genic from various momentum indicators to cycle indicators. When you analyze Genic charts, please remember that the event formation may indicate an entry point for a short seller, and look at different other indicators across different periods to confirm that a breakdown or reversion is likely to occur.
Cycle Indicators | ||
Math Operators | ||
Math Transform | ||
Momentum Indicators | ||
Overlap Studies | ||
Pattern Recognition | ||
Price Transform | ||
Statistic Functions | ||
Volatility Indicators | ||
Volume Indicators |
Risk Adjusted Performance | 0.0821 | |||
Market Risk Adjusted Performance | (0.91) | |||
Mean Deviation | 4.6 | |||
Semi Deviation | 3.99 | |||
Downside Deviation | 4.28 | |||
Coefficient Of Variation | 1078.85 | |||
Standard Deviation | 6.05 | |||
Variance | 36.58 | |||
Information Ratio | 0.0874 | |||
Jensen Alpha | 0.5638 | |||
Total Risk Alpha | 0.3812 | |||
Sortino Ratio | 0.1233 | |||
Treynor Ratio | (0.92) | |||
Maximum Drawdown | 31.77 | |||
Value At Risk | (7.11) | |||
Potential Upside | 12.95 | |||
Downside Variance | 18.36 | |||
Semi Variance | 15.9 | |||
Expected Short fall | (5.96) | |||
Skewness | 1.2 | |||
Kurtosis | 1.85 |
Complementary Tools for Genic Stock analysis
When running Genic's price analysis, check to measure Genic's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Genic is operating at the current time. Most of Genic's value examination focuses on studying past and present price action to predict the probability of Genic's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Genic's price. Additionally, you may evaluate how the addition of Genic to your portfolios can decrease your overall portfolio volatility.
Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
Share Portfolio Track or share privately all of your investments from the convenience of any device | |
Fundamental Analysis View fundamental data based on most recent published financial statements |